Trial Profile

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amoxicillin (Primary) ; Bismuth (Primary) ; Clarithromycin (Primary) ; Rabeprazole (Primary) ; Rifasutenizol (Primary)
Indications Helicobacter pylori infections
Focus Registrational; Therapeutic Use
Sponsors TenNor Therapeutics

18 Nov 2024 Primary endpoint (Eradication rate of H.pylori Strain) has been met, according to a TenNor Therapeutics media release.
18 Nov 2024 Results presented in a TenNor Therapeutics Media Release.
16 Oct 2024 According to a TenNor Therapeutics media release, the company announced closing of series E financing proceeds from which will be used to support the development and to seek regulatory approval in China of rifasutenizol.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com